A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes.

Yuan-Di HalvorsenGeoffrey WalfordTara ThurberHeidy RussellMonica MassaroMason W Freeman

Published in: Diabetes, obesity & metabolism (2019)

Bexagliflozin confers substantial and dose-dependent benefits on subjects with type 2 diabetes and has an acceptable safety profile. Further evaluation of bexagliflozin for the control of type 2 diabetes in adults is warranted.

Keyphrases

placebo controlled
double blind
phase iii
phase ii
clinical trial
phase ii study
study protocol
open label
randomized controlled trial
combination therapy
squamous cell carcinoma